Maravai LifeSciences
MRVI
210 hedge funds and large institutions have $1.18B invested in Maravai LifeSciences in 2024 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 74 increasing their positions, 72 reducing their positions, and 47 closing their positions.
93% more call options, than puts
Call options by funds: $3.48M | Put options by funds: $1.81M
30% more capital invested
Capital invested by funds: $902M → $1.18B (+$274M)
3% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 72
1.67% less ownership
Funds ownership: 104.22% → 102.55% (-1.7%)
6% less funds holding
Funds holding: 223 → 210 (-13)
26% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 47
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$14.8M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$14.8M |
| 3 |
1WCM
12 West Capital Management
New York
|
+$10.8M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$5.94M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$5.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$21.2M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$19.4M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$14M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$8.1M |
| 5 |
EIP
Epoch Investment Partners
New York
|
-$7.46M |
MRVI Hedge Fund Activity: Q1 2024 in Review
210 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q1 2024, worth a combined $1.18B — up 30% from $902M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of MRVI and 35 opened new positions — a net loss of 12 holders — while 72 trimmed existing stakes and 74 added.
The largest buyer was Marshall Wace, adding an estimated $14.8M. The largest seller was Morgan Stanley, cutting an estimated $21.2M.
- 210 institutional investors held Maravai LifeSciences (MRVI) as of Q1 2024, down from 223 in Q4 2023.
- Funds reported $1.18B of Maravai LifeSciences stock for Q1 2024, up 30% quarter-over-quarter.
- 35 funds opened new Maravai LifeSciences positions in Q1 2024 and 47 closed out, a net change of -12 holders.
- The largest Maravai LifeSciences buyer in Q1 2024 was Marshall Wace, an estimated $14.8M added.
- The largest Maravai LifeSciences seller in Q1 2024 was Morgan Stanley, an estimated $21.2M sold.
Based on aggregated 13F filings for Q1 2024.